Spelling suggestions: "subject:"neuropathophysiology"" "subject:"etiopathophysiology""
1 |
Fetal cardiac function predicting fetal compromise: a prospective study冼世源, Sin, Sai-yuen. January 1999 (has links)
published_or_final_version / Medical Sciences / Master / Master of Medical Sciences
|
2 |
The pathophysiology of the coronary slow flow phenomenonTurner, Stuart Peter January 2006 (has links)
The objective of this thesis is to investigate the pathophysiology of the coronary slow phenomenon (CSFP). The experimental work of this thesis has taken a 'bedside to benchtop' approach with clinical observations made in the second chapter guiding the application of basic research techniques in subsequent chapters. Chapter 1 ; The CSFP is a disorder of the coronary microcirculation ; hence chapter 1 specifically reviews the current understanding of this vascular territory and concludes with a summary of the clinical disorders affecting it, concentrating on the CSFP. Chapter 2 ; investigated the angiographic response of the CSFP to a calcium channel blocking agent with antianginal efficacy in this disorder ( mibefradil ). Mibefradil administration was associated with an acute improvement of coronary flow indices which occurred despite background vasodilator therapy with conventional calcium channel antagonists. Chapter 3 ; investigated the in vitro response of human microvessels to mibefradil in comparison to conventional calcium channel blockers. Mibefradil was found to be a more potent agent both in terms of vasodilatation and the prevention of vasoconstriction. Both findings support the clinical observations and point to its selective action on the calcium T channel subtype as a potential mechanism. Chapter 4 ; examined the expression of T type calcium channels at the level of the microvasculature and compared T channel expression in CSFP patients and controls. T channels were found to be expressed at two or more orders of magnitude greater than the L channels. No difference in T channel expression between patients and controls was found. Chapter 5 ; examined the vasomotor reactivity of isolated subcutaneous arterial microvessels to various vasoactive substances between controls and CSFP patients. CSFP patients were found to have a selective hyper reactivity to endothelin. Chapter 6 ; examined plasma endothelin levels in CSFP patients and controls and the relationship between endothelin levels and angina frequency in the CSFP cohort. A small but statistically significant elevation of endothelin-1 was present in patients with the CSFP. A positive association between plasma endothelin fluctuation and angina frequency was also found in the CSFP cohort but not between absolute endothelin levels and angina symptoms. / Thesis (Ph.D.)-- The University of Adelaide, School of Medical Sciences, 2006.
|
3 |
The pathophysiology of the coronary slow flow phenomenonTurner, Stuart Peter January 2006 (has links)
The objective of this thesis is to investigate the pathophysiology of the coronary slow phenomenon (CSFP). The experimental work of this thesis has taken a 'bedside to benchtop' approach with clinical observations made in the second chapter guiding the application of basic research techniques in subsequent chapters. Chapter 1 ; The CSFP is a disorder of the coronary microcirculation ; hence chapter 1 specifically reviews the current understanding of this vascular territory and concludes with a summary of the clinical disorders affecting it, concentrating on the CSFP. Chapter 2 ; investigated the angiographic response of the CSFP to a calcium channel blocking agent with antianginal efficacy in this disorder ( mibefradil ). Mibefradil administration was associated with an acute improvement of coronary flow indices which occurred despite background vasodilator therapy with conventional calcium channel antagonists. Chapter 3 ; investigated the in vitro response of human microvessels to mibefradil in comparison to conventional calcium channel blockers. Mibefradil was found to be a more potent agent both in terms of vasodilatation and the prevention of vasoconstriction. Both findings support the clinical observations and point to its selective action on the calcium T channel subtype as a potential mechanism. Chapter 4 ; examined the expression of T type calcium channels at the level of the microvasculature and compared T channel expression in CSFP patients and controls. T channels were found to be expressed at two or more orders of magnitude greater than the L channels. No difference in T channel expression between patients and controls was found. Chapter 5 ; examined the vasomotor reactivity of isolated subcutaneous arterial microvessels to various vasoactive substances between controls and CSFP patients. CSFP patients were found to have a selective hyper reactivity to endothelin. Chapter 6 ; examined plasma endothelin levels in CSFP patients and controls and the relationship between endothelin levels and angina frequency in the CSFP cohort. A small but statistically significant elevation of endothelin-1 was present in patients with the CSFP. A positive association between plasma endothelin fluctuation and angina frequency was also found in the CSFP cohort but not between absolute endothelin levels and angina symptoms. / Thesis (Ph.D.)-- The University of Adelaide, School of Medical Sciences, 2006.
|
4 |
A proposed pathophysiological role for TNFa in obesity induced cardiac hypertrophyRostami, Maryam 03 1900 (has links)
The a of TNFa in title is the Greek alpha. / Thesis (MSc)--University of Stellenbosch, 2002. / ENGLISH ABSTRACT: Background: Cardiac hypertrophy is an adaptive process occurring in response to
mechanical overload or tissue injury. The stimuli for cardiac hypertrophy are diverse
and vary from increased afterload on the heart to cardiac remodeling in response to
cytokines. Amongst others, obesity is characterized by excessive body weight
resulting in metabolic disorders. This excess body weight necessitates an increased
blood and oxygen delivery to the peripheral tissues, which is achieved by an elevated
cardiac output. Total blood volume is also increased in the obese due to the
increased tissue volume and vascularity. With time, the obesity induced increase in
cardiac preload results in left ventricular hypertrophy and dilatation. Obesity is also
associated with complications such as hypertension, insulin resistance and impaired
glucose metabolism.
In addition, adipose tissue has been implicated to contribute to elevated circulating
TNFa levels in obesity and may contribute to the pathophysiology of the heart in
obese individuals. The heart is a major cytokine-producing organ that generates
amongst others tumor necrosis factor a (TNFa). TNFa is a proinflammatory cytokine,
which acts to increase its own production, has cytotoxic and cytostatic effects on
certain tumor cells and influences growth and differentiation in virtually all cell types
including cardiomyocytes. Elevated levels of TNFa are detected peripherally in
almost all forms of cardiac injury and in hypertrophic cardiomyopathy. These
elevations are proposed to be deleterious to the heart, although an adaptive role for
low levels of TNFa has been proposed. Aim: The aim of the study was to determine whether there is a correlation between
obesity and serum, myocardial, and adipose tissue TNFa levels and cardiac
hypertrophy. We also wished to determine whether the hearts from the obese
animals functioned normally under normoxic conditions and whether they responded
differently to ischaemia/reperfusion when compared with their concurrent controls.
Materials and Methods: Male Sprague-Dawley rats (n=100) were fed a high caloric
diet (HCD) containing 33% rat chow, 33% condensed milk, 7% sucrose and 27%
water, or standard laboratory rat chow for 6-12 weeks. Food consumption, body
weight gain, heart weight and tibia length were measured. Serum glucose, insulin
and lipid levels were also determined. Hearts were excised and perfused on the
isolated Working Heart perfusion apparatus and cardiac function was monitored and
documented. Hearts were then subjected to 15 minutes of total global ischaemia at
370C, and reperfused for 30 minutes. Cardiac function was again documented.
A separate series of hearts were freeze-clamped at different time points during the
experimental protocol and stored in liquid nitrogen for the determination of myocardial
TNFa and cGMP levels. Serum TNFa levels were determined after 12 weeks on the
high caloric or normal/control diet. After 12 weeks on the diet myocardial TNFa levels
of the HCD fed animals and their concurrent controls were determined before and
during ischaemia. Adipose tissue and myocardial tissue TNFa levels were also
determined after 6, 9 and 12 weeks on the respective diets. Myocardial cGMP levels
were measured in the HCD fed rats and the control rats after 6, 9, and 12 weeks.
These data were used as an indirect index to determine whether the myocardial NOcGMP
pathway was activated in the normoxic hearts on the respective diets. Results: The body weight of the HCO fed animals was significantly higher compared
with their respective controls after 12 weeks on the diet (459.9 ± 173.8 g and 271.5 ±
102.6 g respectively (p<0.05». The HCO fed animals also had heart weight to body
weight ratios that were significantly greater compared with the controls (4.2 ± 0.1
mglg and 3.7 ± 0.1 mglg respectively (p<0.05».
The plasma glucose levels of the HCO fed animals were higher than their respective
controls (9.2 ± 0.3 mmoiII and 7.8 ± 0.3 mmoiII respectively (p<0.05)), but their insulin
levels were similar (12.87 ± 1.02 IlIUlml and 12.42 ± 5.06 IlIU/ml). Plasma lipid
profiles (plasma cholesterol, high density lipoprotein (HOL) cholesterol and plasma
triacylglyceride (TAG)) were abnormal in the HCO fed animals compared with the
control rats. Plasma TAG levels in the HCO fed animals were significantly higher
compared with the control rats (0.664 ± 0.062 mmoiII and 0.503 ± 0.043 (p<0.05»,
while plasma cholesterol levels (1.794 ± 0.058 mmoIII and 2.082 ± 0.062 mmoiII
(p<0.05» and HOL cholesterol levels were significantly lower (1.207 ± 0.031 mmoiII
and 1.451 ± 0.050 mmoiII (p<0.05».
Cardiac mechanical function was similar for both groups before ischaemia, but the
percentage aortic output recovery was lower for the hearts from the HCO fed animals
when compared with their controls (47.86 ± 7.87% and 66.67 ± 3.76 % respectively
(p<0.05».
Serum TNFa levels of the HCO fed animals were higher compared with the control
animals (51.04 ± 5.14 AU and 31.46 ± 3.72 AU respectively (p<0.05», but myocardial
TNFa levels remained lower in these animals (312.0 ± 44.7 pglgram ww and 571.4 ± 132.9 pg/gram ww respectively (p<0.05)). During ischaemia these myocardial TNFa
levels increased above those of the controls (442.9 ± 12.4 pg/gram ww and 410.0 ±
12.5 pg/gram ww respectively (p<0.05)). The adipose tissue TNFa levels were
significantly increased after 12 weeks on the high caloric diet compared with the
control animals (4.4 ± 0.4 pg/gram ww and 2.5 ± 0.3 pg/gram ww respectively
(p<0.05)). There was no significant difference in the myocardial cGMP levels of the
HCD rats compared with the conrol rats after 6, 9 and 12 weeks.
Conclusion: 1) The high caloric diet induced obesity, which lead to cardiac
hypertrophy in this study. 2) There was a strong correlation between elevated
adipose tissue and serum TNFa levels, and cardiac hypertrophy. 3) Elevated serum
TNFa levels did not lead to activation of the myocardial NO-cGMP pathway in the
normoxic hearts in this model. 4) The hypertrophied hearts from the HCD fed animals
had poorer post-ischaemie myocardial functions than their concurrent controls. / AFRIKAANSE OPSOMMING: Agtergrond: Miokardiale hipertrofie is In aanpassing wat gebeur as In gevolg van
meganiese oorbelading of weefsel beskadiging. Verskillende stimuli kan tot
miokardiale hipertrofie aanleiding gee soos byvoorbeeld In verhoging in nalading, of
miokardiale hermodellering in respons op sitokiene. Verhoging van voorbelading in
vetsug mag ook tot hipertrofie aanleiding gee. Vetsug word gekenmerk deur In
oormatige liggaamsmassa wat tot metaboliese versteurings lei. Die oormatige
liggaamsmassa vereis In verhoging in bloed- en suurstofverskaffing aan die perifere
weefsel wat deur In verhoging in die kardiale uitset vermag kan word. Die bloed
volume van In vetsugtige individu word ook verhoog as gevolg van In verhoging in
weefselvolume en vaskulariteit en met verloop van tyd induseer die verhoogde
kardiale voorbelading linker ventrikulêre hipertrofie en dilatasie. Vetsug word ook met
verskeie ander siekte toestande soos hipertensie, insulien weerstandigheid en
versteurde glukose metabolisme, geassosieer.
Vetweefsel dra ook by tot verhoging van tumor nekrose faktor alfa (TNFa) vlakke in
die bloed, wat op sy beurt tot miokardiale hipertrofie mag bydra. TNFa is In proinflammatoriese
sitokien wat sy eie produksie kan stimuleer. Dit het ook sitotoksiese
en sitostatiese effekte op sekere tumor selle en kan groei en differensiasie in bykans
alle seltipes, insluitende kardiomiosiete, stimuleer. Die hart kan ook TNFa produseer
en verhoogde TNFa vlakke word feitlik in alle vorms van miokardiale besering en
hipertrofiese kardiomiopatie waargeneem. Daar word voorgestel dat verhoogde
TNFa vlakke vir die hart nadelig is, ten spyte van die vermoeding dat die sitokien In
potensiële aanpassings rol by laer vlakke het. Doelstelling: Die doel van hierdie studie was om vas te stelof daar 'n verband tussen
vetsug en serum, miokardiale en vetweefsel TNFa vlakke en miokardiale hipertrofie,
bestaan. Ons het ook gepoog om te bepaal of harte van vetsugtige diere normaal
funksioneer en of die response van sulke harte op isgemie-herperfusie van die van
ooreenstemmende kontroles verskil.
Materiaal en tegnieke: Manlike Sprague-Dawley rotte (n=100) is vir 6-12 weke op 'n
hoë kalorie dieët (HKD) geplaas. Die HKD het uit 33% rotkos, 33% gekondenseerde
melk, 7% sukrose en 27% water bestaan. Kontrole diere het standaard laboratorium
rotkos ontvang. Voedselinname, liggaamsmassa toename, serum insulien, glukose
en lipied vlakke is ook bepaal. Harte is geïsoleer en geperfuseer volgens die Werk
Hart perfusie metode en hart funksie is gemonitor en gedokumenteer. Harte is
vervolgens aan 15 minute globale isgemie by 3rC blootgestel en daarna weer vir 30
minute geherperfuseer waartydens hartfunksie weer gedokumenteer is. 'n Aparte
groep harte is op spesifieke tydsintervalle gedurende die eksperimentele protokol
gevriesklamp en in vloeibare stikstof gestoor vir die bepaling van miokardiale TNFa
en sGMP vlakke.
Serum TNFa vlakke is bepaal na 12 weke op die dieët. Na die diere 12 weke op die
HKD was, is hierdie diere en hulooreenstemmende kontroles se miokardiale TNFa
vlakke voor en na isgemie bepaal. Vetweefsel en miokardiale TNFa vlakke is ook
onderskeidelik na 6, 9 en 12 weke bepaal. Miokardiale sGMP vlakke is in die HKD
diere en in die kontrole diere na 6, 9 en 12 weke bepaal. sGMP vlakke is gebruik as
'n indirekte indeks van aktivering van die miokardiale NO-sGMP boodskapper pad. Resultate: Na 12 weke op die dieët was die liggaamsmassa van die HKD diere
beduidend hoër in vergeleke met hulooreenstemmende kontroles (459.9 ± 173.8 g
en 271.5 ± 102.6 g (p<0.05)). Die HKD diere se hart massa tot liggaam massa
verhouding was ook beduidend hoër in vergelyking met die van kontroles (4.2 ± 0.1
mglg en 3.7 ± 0.1 mglg (p<0.05)).
Alhoewel insulien vlakke dieselfde was (12.42 ± 5.06 j.lIU/ml en 12.87 ± 1.02 j.lIU/ml),
was serum glukose vlakke van die HKD diere hoër as die van die ooreenstemmende
kontroles (9.2 ± 0.3 mmoiii en 7.8 ± 0.3 mmoiii (p<0.05)). Plasma lipied profiele (HOL
cholesterol, plasma cholesterol en trigliseriede) was abnormaal in die HKD diere.
Plasma TAG vlakke in die HKD diere was beduidend hoër as die van die kontroles
(0.664 ± 0.062 mmoiii en 0.503 ± 0.043 (p<0.05)), terwyl plasma cholesterol vlakke
(1.794 ± 0.058 mmoiii en 2.082 ± 0.062 mmoiii (p<0.05)) en HOL cholesterol vlakke
beduidend laer was (1.207 ± 0.031 mmoiii en 1.451 ± 0.050 mmoiii (p<0.05)).
Miokardiale meganiese funksie was dieselfde vir beide groepe voor isgemie, maar
die persentasie aorta omset herstel tydens herperfusie was laer in die HKD diere in
vergelyking met die van kontrole diere (47.86 ±. 7.87% en 66.67 ± 3.76% (p<0.05)).
Serum TNFa vlakke van die HKD diere was beduidend hoër as die van kontrole diere
(51.04 ± 5.14 AU en 31.46 ± 3.72 AU (p<0.05)), maar miokardiale TNFa vlakke was
laer (312.0 ± 44.7 pglgram nat gewig en 571.4 ± 132.9 pglgram nat gewig (p<0.05)).
Die vetweefsel TNFa vlakke was ook beduidend verhoog na 12 weke op "n hoë
kalorie dieët wanneer dit vergelyk word met die van kontrole diere (4.4 ± 0.4 pglgram
nat gewig en 2.5 ± 0.3 pglgram nat gewig respektiewelik (p<0.05)). Daar was geenbeduidende verskille in die miocardiale vlakke van sGMP in die HKD diere in
vergelyking met die kontroles na 6, 9 en 12 weke.
Gevolgtrekkings: 1) "n Hoë kalorie dieët het in dié studie vetsug geïnduseer en tot
miokardiale hipertrofie gelei. 2) Daar was "n positiewe korrelasie tussen verhoogde
vetweefsel en serum TNFa vlakke, en miokardiale hipertrofie. 3) Verhoogde serum
TNFa vlakke het nie tot die aktivering van die miokardiale NO-sGMP pad in hierdie
model gelei nie. 4) Die hipertrofiese harte het tydens herperfusie ná isgemie swakker
as hulooreenstemmende kontroles gefunksioneer.
|
5 |
Influence of natriuretic peptides on cardiac reflexesThomas, Colleen J(Colleen Joy),1965- January 2001 (has links)
Abstract not available
|
6 |
Elucidating the Unknown Role of Cyclin Dependent Kinase 5 in Cardiac Pathophysiological ConditionsAina-Badejo, Danielle January 2021 (has links)
Until now, the role of cyclin dependent kinase 5 (CDK5) in cardiac pathophysiology has not been explored. While CDK5 has been well studied in the neuroscience/Alzheimer’s field as a cyclin-independent kinase, there is currently no investigation into the cardiac-specific role of CDK5. Recently, it was established that inhibition of CDK5 in stem cell derived cardiomyocytes from individuals with Timothy Syndrome (TS) rescued the delayed inactivation phenotype; TS is a fatal genetic long QT syndrome (LQTS) caused by delayed inactivation of the L-type voltage gated Ca2+channel CaV1.2. While it is evident that CDK5 plays an important role in regulating CaV1.2 function, its role in cardiac tissue remains to be elucidated.
To determine whether CDK5 is essential for cardiac function, two separate mouse models were established—a cardiac-deficient Cdk5 mouse model (Cdk5 flox x αMHC-MerCreMer+) and a Cdk5 activation mouse model via overexpression of Cdk5’s known activator, p35 (Cdk5r1/p35 OE x αMHC-MerCreMer+). Immediately after spatiotemporal induction of deficiency/activation of Cdk5 in adult mice, echocardiography, histology and proteomic analysis were performed to examine effects on cardiac structure and function. Analysis of cardiac function and morphology in Cdk5 deficient mice revealed severe systolic dysfunction and a dilated cardiomyopathy-like phenotype. These results were further validated by a pathway analysis of quantified global proteome changes. Conversely, mice with an activation of Cdk5 displayed only minor changes in cardiac function with a modest reduction in fractional shortening and ejection fraction. Notably, these mice did not have any significant changes in cardiac chamber morphology, nor any significant changes to their global proteome. Interestingly, however, phosphoproteomic analysis revealed over 3,000 differentially phosphorylated proteins.
Pathway and gene ontology analysis of proteome changes revealed significant hits related to cell adhesion. Evidence for the extensively studied role of CDK5 in the brain has demonstrated a critical role for CDK5 kinase activity in the regulation of cell adhesion. Alterations in cell adhesion are observed in a number of cardiac pathologies including heart failure and dilated cardiomyopathy; it is therefore plausible that CDK5 potentially regulates cardiac function via cell adhesion mechanisms. A comparison of the phospho-proteome acutely after Cdk5 depletion vs the phospho-proteome acutely after Cdk5 activation, allowed for the identification of a novel cardiac-specific Cdk5 substrate, beta taxilin (Txlnb). Validation of this potential phospho-substrate with an in situ proximity ligation assay demonstrated the co-localization of Cdk5-Txlnb in wildtype mouse cardiac tissue sections. When looking at co-localization in Cdk5 deficient tissue sections, no signals were observed.
Lastly, our lab obtained donor cardiac tissue samples from individuals who passed away due to either heart failure or non-cardiac causes (serving as control cardiac tissue). Analysis of cardiac tissue samples revealed a significant increase in both CDK5 and p35 expression in heart failure samples. Dysregulation of phosphorylation has been implicated in cardiac dysfunction, with known contribution to contractile failure and a number of cardiac pathologies including cardiomyopathies. These findings further support a role for CDK5 in cardiac function.
In conclusion, it appears that CDK5 is imperative for the maintenance of healthy cardiac function. Cardiac-specific homozygous and heterozygous Cdk5 deficiency revealed severe systolic dysfunction along with a dilated cardiomyopathy-like phenotype. While the effects of Cdk5 activation in the heart need to be further investigated, initial findings report significant downstream effects on the phosphorylation of a number of proteins, including Txlnb. Moreover, Txlnb was identified as a potential novel cardiac-specific substrate of Cdk5.
The importance of identifying a role for CDK5 in the heart extends beyond this study. CDK inhibitors have been at the forefront of drug development for cancer therapeutics and immunotherapy. While modulation of CDK5 activity may be beneficial in one physiological system, it may prove deleterious in another. It is therefore imperative that the full range of molecular and physiological roles of each CDK be fully elucidated prior to therapeutic application. Furthermore, outcomes from this study have the potential to be translational for drug discovery and the development of new therapeutic avenues for heart disease.
|
7 |
Identification and characterization of altered mitochondrial protein acetylation in Friedreich's ataxia cardiomyopathyWagner, Gregory Randall January 2011 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Friedreich’s Ataxia (FRDA) is a rare and poorly understood autosomal recessive disease caused by a pathological deficiency of the mitochondrial protein frataxin. Patients suffer neurodegeneration, ataxia, diabetes, and heart failure. In an effort to understand the mechanisms of heart failure in FRDA, we investigated the role of the protein modification acetylation, which is highly abundant on mitochondrial proteins and has been implicated in regulating intermediary metabolism. Using mouse models of FRDA, we found that cardiac frataxin deficiency causes progressive hyperacetylation of mitochondrial proteins which is correlated with loss of respiratory chain subunits and an altered mitochondrial redox state. Mitochondrial protein hyperacetylation could be reversed by the mitochondria-localized deacetylase SIRT3 in vitro, suggesting a defect in endogenous SIRT3 activity. Consistently, frataxin-deficient cardiac mitochondria showed significantly decreased rates of fatty acid oxidation and complete oxidation to carbon dioxide. However, the degree of protein hyperacetylation in FRDA could not be fully explained by SIRT3 loss. Our data suggested that intermediary metabolites and perhaps acetyl-CoA, which is required for protein acetylation, are accumulating in frataxin-deficient mitochondria. Upon testing the hypothesis that mitochondrial protein acetylation is non-enzymatic, we found that the minimal chemical conditions of the mitochondrial matrix are sufficient to cause widespread non-enzymatic protein acetylation in vitro. These data suggest that mitochondrial protein hyperacetylation in FRDA cardiomyopathy mediates progressive post-translational suppression of mitochondrial oxidative pathways which is caused by a combination of SIRT3 deficiency and, likely, an accumulation of unoxidized acetyl-CoA capable of initiating non-enzymatic protein acetylation. These findings provide novel insight into the mechanisms underlying a poorly understood and fatal cardiomyopathy and highlight a fundamental biochemical mechanism that had been previously overlooked in biological systems.
|
8 |
In situ three-dimensional reconstruction of mouse heart sympathetic innervation by two-photon excitation fluorescence imagingFreeman, Kim Renee 25 February 2014 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / The sympathetic nervous system strongly modulates the contractile and electrical function of the heart. The anatomical underpinnings that enable a spatially and temporally coordinated dissemination of sympathetic signals within the cardiac tissue are only incompletely characterized. In this work we took the first step of unraveling the in situ 3D microarchitecture of the cardiac sympathetic nervous system. Using a combination of two-photon excitation fluorescence microscopy and computer-assisted image analyses, we reconstructed the sympathetic network in a portion of the left ventricular epicardium from adult transgenic mice expressing a fluorescent reporter protein in all peripheral sympathetic neurons. The reconstruction revealed several organizational principles of the local sympathetic tree that synergize to enable a coordinated and efficient signal transfer to the target tissue. First, synaptic boutons are aligned with high density along much of axon-cell contacts. Second, axon segments are oriented parallel to the main, i.e., longitudinal, axes of their apposed cardiomyocytes, optimizing the frequency of transmitter release sites per axon/per cardiomyocyte. Third, the local network was partitioned into branched and/or looped sub-trees which extended both radially and tangentially through the image volume. Fourth, sub-trees arrange to not much overlap, giving rise to multiple annexed innervation domains of variable complexity and configuration. The sympathetic network in the epicardial border zone of a chronic myocardial infarction was observed to undergo substantive remodeling, which included almost complete loss of fibers at depths >10 µm from the surface, spatially heterogeneous gain of axons, irregularly shaped synaptic boutons, and formation of axonal plexuses composed of nested loops of variable length. In conclusion, we provide, to the best of our knowledge, the first in situ 3D reconstruction of the local cardiac sympathetic network in normal and injured mammalian myocardium. Mapping the sympathetic network connectivity will aid in elucidating its role in sympathetic signal transmisson and processing.
|
9 |
Dimorphisme sexuel dans les manifestations métaboliques et cardiaques de la stéatose hépatique non-alcoolique sans obésité révélée par l’étude d’un nouveau modèle murinBurelle, Charlotte 10 1900 (has links)
Les patients atteints de stéatose hépatique non alcoolique (NAFLD) développent fréquemment des manifestations cardiovasculaires. Bien que souvent liées à l'obésité, ces anomalies peuvent également se développer chez des patients non obèses atteints de NAFLD impliquant que cette pathologie hépatique joue, en soi, un rôle dans la pathogenèse des complications cardiaques.
Pour répondre à cette question et étudier les mécanismes sous-jacents indépendamment de toutes perturbations métaboliques et comorbidités préexistantes, nous avons utilisé un modèle murin arborant une déficience mitochondriale hépatique associée à un défaut d'assemblage du complexe IV de la chaîne respiratoire. Ce modèle murin avait préalablement été caractérisé au niveau hépatique mettant alors en évidence le développement d'une stéatose microvésiculaire et un profil lipidomique similaire à celui observé chez les patients atteints d'une NAFLD sans obésité. L'identification des mécanismes qui sous-tendent le développement et la progression de la NAFLD sans obésité et de ces répercussions extra-hépatiques ne faisant pas l'objet d'un très grand nombre d'études fondamentales, l'objectif principal était donc d'étudier l'axe foie-coeur.
Dans le cadre des travaux de ce mémoire, nous avons cherché à approfondir la caractérisation hépatique, préalablement faite à l'âge de 5 semaines et ayant fait l'objet de publications par des laboratoires collaborateurs. Nous avons par la suite investigué la glycémie, l'insulinémie et le profil des lipoprotéines plasmatiques pour finir par l'analyse du métabolisme et de la fonction cardiaque. L'ensemble de ces expériences ont été faites en prenant en compte l'impact non négligeable du sexe sur la physiopathologie de la NAFLD. Nos résultats ont dévoilé un important remodelage phénotypique sexe-dépendant allant au-delà des lésions hépatiques. Les mâles un peu plus que les femelles présentaient une hypoglycémie à jeun et une sensibilité accrue à l'insuline. Ils présentaient un léger dysfonctionnement diastolique soutenu par un remodelage des lipoprotéines circulantes et dans une certaine mesure, par un remodelage du lipidome cardiaque. À l'inverse, les femelles ne manifestaient aucun dysfonctionnement cardiaque, mais présentaient des déficiences cardiométaboliques soutenues par une altération de l’intégrité et la fonction mitochondriale, un remodelage des lipoprotéines circulantes et une accumulation intracardiaque de triglycérides.
À la lumière de ces résultats, cette étude souligne que les défauts métaboliques dans le foie peuvent entraîner des anomalies significatives et dépendantes du sexe affectant à la fois le phénotype mitochondrial/métabolique et la fonction contractile indépendamment de l'obésité. Ce modèle expérimental pourrait s'avérer utile dans la compréhension des mécanismes sous-jacents à la variabilité liée au sexe dans la progression de la NAFLD chez l'homme non obèse. / Cardiac abnormalities often develop in patients with non-alcoholic fatty liver disease (NAFLD). Although frequently linked to obesity, these abnormalities can also develop in patients with lean-NAFLD, implying that the liver pathology per se plays a role in the pathogenesis of cardiac complications.
To address this question and investigate the underlying mechanisms independent of any pre-existent metabolic disruptions and comorbidities, we used a murine model of hepatic mitochondrial deficiency associated with a defect in the assembly of respiratory chain complex IV. This mouse model had previously been characterized at the hepatic level, showing the presence of microvesicular steatosis, and a lipidomic profile similar to that observed in patients with lean-NAFLD. Because few fundamental studies have adressed the identification of mechanisms underlying the development and progression of lean-NAFLD and its extrahepatic repercussions, the main aim was to study the liver-heart axis.
As a part of this master's project, we sought to deepen the hepatic characterization of this mouse model, previously done at 5-weeks of age, and published by collaborators. We then investigated glycemia, insulinemia and plasma lipoprotein profile, and finally examined cardiac metabolism and function. All these experiments were done in consideration of the non-negligible impact of sexe on the pathophysiology of NAFLD. Our results unveiled a sex-dependent multi-faceted phenotypic remodeling that went beyond liver damage. Males, slightly more than females, showed fasting hypoglycemia and increased insulin sensitivity. They exhibited mild diastolic dysfunction supported by remodeling of the circulating lipoproteins, and to some extent remodeling of cardiac lipidome. Conversely, females did not manifest cardiac dysfunction, but exhibited cardiometabolic impairments supported by impaired mitochondrial integrity and function, remodeling of circulating lipoproteins, and intracardiac accumulation of triglycerides.
In light of these findings, this study underscores that metabolic defects in the liver can result in significant sex-dependent abnormalities that affect both the mitochondrial/metabolic phenotype and contractile function independent of obesity. This experimental model may prove useful to better understand the mechanisms underlying the sex-related variability in the progression of lean-NAFLD in humans.
|
Page generated in 0.0623 seconds